Federal Register: July 14, 2005 (Volume 70, Number 134)
DOCID: FR Doc 05-13856
DEPARTMENT OF DEFENSE
Army Department
NOTICE: NOTICES
ACTION: Patent licenses; non-exclusive, exclusive, or partially exclusive:
DOCUMENT ACTION: Notice.
SUBJECT CATEGORY:
Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Applications Concerning Inhibitors of Type F Botulinum Neurotoxin Proteinase Activity
DOCUMENT SUMMARY:
In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 60/656,551 entitled ``Inhibitors of Type F Botulinum Neurotoxin Proteinase Activity,'' filed February 17, 2005; as well as the invention set forth in related U.S. Provisional Patent application Serial No. 60/660,024 entitled ``Inhibitors of Type F Botulinum Neurotoxin Proteinase Activity,'' filed February 23, 2005. The United States Government, as represented by the Secretary of the Army, has rights in this invention.
SUMMARY:
Inhibitors of type F botulinum neurotoxin proteinase activity,
SUPPLEMENTAL INFORMATION
Botulinum neurotoxins (BoNTs A-G) are zinc
metalloendoproteases that exhibit extraordinary specificities for
proteins involved in neurotransmitter release. In view of the extreme
toxicities of these molecules, their applications in human medicine,
and potential for misuse, it is of considerable importance to elucidate
the mechanisms underlying substrate recognition and to develop
inhibitors, with the ultimate goal of obtaining antibotulinum drugs. Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 0513856 Filed 71305; 8:45 am]
BILLING CODE 371008M
FOR FURTHER INFORMATION CONTACT
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 6197808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 6196664, both at telefax (301) 6195034.